Primary tumor size as a prognosticator in anal cancer patients

Combination therapy with concurrent chemo-radiation is considered the standard therapeutic option for anal cancer patients, providing both tumor eradication and sphincter preservation (1). Survival rates depend on the global stage at presentation ranging from 60% to 80% at 3–5 years (2-4).